Results 51 to 60 of about 3,241 (183)
Xiehe Yixue Zazhi, 2022 Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a highly malignant hematological tumor derived from the precursor cells of plasmacytoid dendritic cells.
CHEN Xiaojun +4 more
doaj +1 more source
Human plasmacytoid dendritic cells and cutaneous melanoma [PDF]
, 2020 The prognosis of metastatic melanoma (MM) patients has remained poor for a long time. However, the recent introduction of effective target therapies (BRAF and MEK inhibitors for BRAFV600-mutated MM) and immunotherapies (anti-CTLA-4 and anti-PD-1) has ...
Bugatti, Mattia +4 more
core +2 more sources
E-cadherin expression and blunted interferon response in blastic plasmacytoid dendritic cell neoplasm [PDF]
, 2021 Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive neoplasm derived from plasmacytoid dendritic cells (pDCs). In this study, we investigated by immunohistochemical analysis the expression of E-cadherin (EC) on pDCs in reactive lymph ...
Arisi, Mariachiara +12 more
core +2 more sources
Cytometry Part B: Clinical Cytometry, EarlyView.Abstract Systemic mastocytosis (SM) is a clonal mast cell (MC) disorder characterized by aberrant immunophenotypes, including expression of CD25, CD2, and occasionally CD30. CD123, the α‐subunit of the interleukin‐3 receptor, is a therapeutic target in hematologic malignancies and has been reported to be expressed on neoplastic MCs by ...
Ryan C. Shean +2 more
wiley +1 more source
Clinical Medicine Insights: Case Reports, 2013 Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive myeloid neoplasm derived from plasmacytoid monocytes. The most common presentation involves cutaneous manifestations, which are often accompanied by bone marrow involvement.
Lindsey Prochaska +2 more
doaj +1 more source
Leukemia Research Reports, 2022 Blastic plasmacytoid dendritic cell neoplasm usually presents as skin lesions. Diagnostic error occurs when it primarily presents in leukemic phase without skin involvement.
Hareem Alam, Nabiha Saeed, Anila Rashid
doaj +1 more source
Cancer Science, EarlyView.An immune dysfunction score (IDS) provides independent prognostic information in MDS and CMML, complements current risk models, mirrors disease changes, and reflects underlying immune impairment. IDS may also highlight therapeutic sensitivities, supporting its use as a practical biomarker for risk stratification and clinical follow‐up.
Yu‐Hung Wang +16 more
wiley +1 more source
Neoplasia Blástica de Células Dendríticas Plasmocitóides [PDF]
, 2013 Blastic plasmacytoid dendritic cell neoplasm is a rare and aggressive hematodermic neoplasia with frequent cutaneous involvement and leukemic dissemination. We report the case of a 76-year-old man with a 2 month history of violaceous nodules and a tumor
Cabete, J +5 more
core
Whole-genome analysis uncovers recurrent IKZF1 inactivation and aberrant cell adhesion in blastic plasmacytoid dendritic cell neoplasm [PDF]
, 2020 Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and highly aggressive hematological malignancy with a poorly understood pathobiology and no effective therapeutic options.
A.N. Bastidas Torres +10 more
core +1 more source
International Journal of Laboratory Hematology, EarlyView.ABSTRACT Introduction Neutrophil‐extracellular traps are net‐like material released by triggered neutrophils and composed of decondensed chromatin linked to nuclear proteins. Elastase, one of the fourth most represented neutrophil‐specific serine proteases stored in azurophil granules of naïve neutrophils, exerts various actions, including degradation ...
Pasqualina Scala +14 more
wiley +1 more source